Rapport Therapeutics (NASDAQ:RAPP) Earns “Buy” Rating from HC Wainwright

Rapport Therapeutics (NASDAQ:RAPP)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Tuesday, MarketBeat.com reports. They currently have a $66.00 price objective on the stock. HC Wainwright‘s target price would suggest a potential upside of 149.46% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. UBS Group assumed coverage on shares of Rapport Therapeutics in a research note on Thursday, October 15th. They set a “buy” rating and a $71.00 price objective for the company. Leerink Partners assumed coverage on shares of Rapport Therapeutics in a research note on Wednesday, June 24th. They set an “outperform” rating and a $52.00 price objective for the company. Guggenheim initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, October 6th. They set a “buy” rating and a $65.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, October 15th. Finally, Citigroup reissued a “market outperform” rating on shares of Rapport Therapeutics in a report on Wednesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Rapport Therapeutics has an average rating of “Buy” and an average target price of $68.36.

Rapport Therapeutics Trading Down 0.3%

Shares of NASDAQ:RAPP opened at $26.46 on Tuesday. Rapport Therapeutics has a 12 month low of $23.75 and a 12 month high of $52.93. The company has a 50-day moving average price of $39.44 and a 200 day moving average price of $39.02. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -8.68 and a beta of 1.22.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). As a group, equities analysts forecast that Rapport Therapeutics will post -4.09 EPS for the current year.

Insider Buying and Selling at Rapport Therapeutics

In related news, CFO Troy A. Ignelzi purchased 5,500 shares of Rapport Therapeutics stock in a transaction dated Wednesday, October 21st. The shares were acquired at an average price of $26.10 per share, for a total transaction of $143,550.00. Following the acquisition, the chief financial officer directly owned 15,500 shares in the company, valued at approximately $404,550. The trade was a 55.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steven M. Paul bought 35,714 shares of the business’s stock in a transaction on Thursday, October 22nd. The shares were acquired at an average cost of $27.28 per share, with a total value of $974,277.92. Following the purchase, the director owned 77,380 shares of the company’s stock, valued at $2,110,926.40. The trade was a 85.71% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have bought 58,094 shares of company stock valued at $1,566,358 and have sold 97,976 shares valued at $4,420,349. Company insiders own 12.48% of the company’s stock.

Hedge Funds Weigh In On Rapport Therapeutics

Hedge funds have recently made changes to their positions in the stock. Algert Global LLC purchased a new position in shares of Rapport Therapeutics during the 2nd quarter worth approximately $9,327,000. Johnson & Johnson acquired a new stake in Rapport Therapeutics during the 2nd quarter worth approximately $74,360,823. Legal & General Group Plc acquired a new stake in Rapport Therapeutics during the 2nd quarter worth approximately $940,000. Walleye Capital LLC acquired a new stake in Rapport Therapeutics during the 2nd quarter worth approximately $4,257,000. Finally, Bank of New York Mellon Corp acquired a new stake in Rapport Therapeutics during the 2nd quarter worth approximately $3,426,000.

Trending Headlines about Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The treatment produced statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. The results could materially expand RAP-219’s commercial opportunity beyond epilepsy. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts raised or maintained bullish ratings and price targets. JonesTrading raised its target from $50 to $82 and assigned a Buy rating. BTIG reportedly increased its target to $89, while HC Wainwright reaffirmed its Buy rating. The analyst actions reinforce optimism about RAP-219’s potential market opportunity. Rapport Therapeutics analyst price target news
• Positive Sentiment: Company insiders made substantial open-market purchases. CFO Troy Ignelzi bought 5,500 shares for approximately $143,550, while four directors purchased a combined 52,594 shares worth roughly $1.43 million. These transactions may signal management confidence following the clinical update. Rapport Therapeutics insider purchase filings
• Neutral Sentiment: The clinical progress and planned Phase 3 program improve Rapport’s long-term prospects, but investors must still consider regulatory, financing, execution, and commercialization risks before any potential approval.
• Negative Sentiment: Some investors viewed the clinical data as less decisive than hoped. Reports suggested portions of the results only narrowly exceeded expectations, which could limit the durability of the rally. Rapport also remains unprofitable; its latest quarterly loss missed consensus, and analysts expect a full-year loss of approximately $4.09 per share. Rapport Therapeutics bipolar mania data analysis

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.